Tafamidis is used in the therapy of transthyretin amyloid cardiomyopathy (ATTR-CM), which has proven its benefit in the ATTR-ACT clinical study. The results of its open-label extension study show that early diagnosis and prompt initiation of therapy are crucial.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
